The debate on alogliptin hepatotoxicity has recently aroused interest after a narrative review on hepatic safety of incretin-based therapies [1] . In fact, Scheen concluded that the overall liver safety of dipeptidyl peptidase-4 inhibitors (DPP-4-I) is reassuring, with the explicit statement that ''no hepatotoxicity has been reported in the development programme of alogliptin''. In contrast, Barbehenn et al. [2] questioned these conclusions by detailing the US FDA hepatological assessment and perusing data from the Examination of Cardiovascular Outcomes with Alogliptin Versus Standard of Care (EXAMINE) trial, where a numerical imbalance, albeit not statistically significant, emerged for alogliptin [3] . The updated data provided by Scheen [4] indicate that ''alogliptin is associated with a low risk of hepatic toxicity'' and challenge the FDA liver panel test before starting alogliptin therapy.
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Since premarketing randomized clinical trials are not designed to and are underpowered to detect rare adverse effects, large spontaneous reporting systems of adverse drug reactions are a pivotal source for early identification of safety signals. Thus, we offer our contribution by analyzing the publicly available FDA Adverse Event Reporting System (FAERS). This type of analysis, notwithstanding recognized limitations, is likely to reflect actual clinical practice (i.e. patients with comorbidities and polypharmacotherapy) and is very informative to profile the hepatic risk, especially for newly marketed drugs, and potentially initiate timely postmarketing evaluation [5] . In fact, we believe that the observed numerical imbalance in clinical trials justifies this relatively quick and inexpensive analysis, as previously done for pioglitazone and bladder cancer [6] .
We analyzed the latest FAERS reports where DPP-4-I were reported as the primary/secondary suspect or interacting drugs (reports with drug combinations were not counted to avoid overestimation) from quarter 4 (Q4) 2006-marketing authorization of the first-in-class DPP-4-I, sitagliptin-to Q4 2013, according to an already implemented data mining algorithm [7] and based on a validated search strategy [8, 9] : adverse event reports of overall liver injury (OLI, including acute and chronic hepatic injuries) and acute liver failure (ALF, a subcategory including only acute severe hepatic injuries) were extracted and the disproportionality approach was performed by calculating the reporting odds ratio (ROR) with 95 % confidence interval (CI). A signal was traditionally defined by statistically significant ROR (lower limit of the 95 % CI [1) with at least three reports.
We found two key results: (1) no signal of liver injury emerged for alogliptin; and (2) statistically significant association was found for OLI with sitagliptin, saxagliptin and vildagliptin (the only agent without US approval) ( Table 1) . With regard to alogliptin, the lack of signal also persisted after restricting the analysis to relevant time (i.e. Q1 2013-Q4 2013) on the market (data not shown).
Although pharmacokinetic and chemical properties have been claimed to have a role in drug-induced hepatic injury, pharmacokinetic features can only partially explain these data. In fact, only saxagliptin metabolic products of hepatic biotransformation are minimally active and may contribute to generating intermediate reactive metabolites with a potential role in hepatic damage [10] .
Our data should be interpreted with caution but raise concern and increase complexity in the assessment of actual liver risk associated with gliptins. In particular, the heterogeneous marketing life, penetration and utilization of the different compounds suggest the need for further postmarketing investigation through population-based studies to gain insight into possible class effect. Although it is reassuring to observe, with the exception of sitagliptin, the very low number of ALF reports (i.e. serious events), it should be also emphasized that both US and European labels of sitagliptin do not contain any mention of liver risk in the relevant sections [11, 12] .
Although, according to our data, the alogliptin label appears over-restrictive, we hypothesized that the recent marketing authorization and the FDA (precautionary) recommendations of mandatory hepatic monitoring before and during alogliptin administration may have contributed to minimize the risk of liver injury by channelling a susceptible population (i.e. excluding diabetic patients with baseline hepatic enzyme elevation). Thus, we believe that monitoring liver function (especially in patients with recent changes in treatment regimens) is justified to timely intercept potentially serious liver events; we endorse the FDA approach (i.e. enhanced pharmacovigilance programme to monitor liver abnormalities and current label content) to ensure patient's safety.
Based on our data, extending recommendations of liver monitoring to all gliptins, especially before starting treatment, may be considered until dedicated analytical (casecontrol and cohort) studies will resolve the issue of class effect. 
